Live Breaking News & Updates on Excel Hospital

Stay updated with breaking news from Excel hospital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Natco Pharma surges 20%, hits new high on USFDA nod for cancer drug


Shares of Natco Pharma surged 20 per cent to Rs 1,188.95, also its new high, on the BSE in intra-day trade on Monday after the company said it has received approval from the US health regulator for the generic version of Celgene s multiple myeloma drug, Revlimid (Lenalidomide) capsules in US. Lenalidomide capsule is indicated for treatment of adults with multiple myeloma, mantle cell lymphoma and myelodysplastic syndromes.
In the past three days, the stock has zoomed 30 per cent. At 09:48 am, Natco Pharma was trading 11 per cent higher at Rs 1,101 on the BSE, as compared to 0.24 per cent rise in the S&P BSE Sensex. The trading volumes on the counter jumped over five-fold with a combined 3.8 million equity shares changing hands on the NSE and BSE. ....

Andhra Pradesh , Revlimid Lenalidomide , Natco Pharma , Drug Administration , Breckenridge Pharmaceutical Inc , Abbreviated New Drug Application , Molnupiravir Capsules , Yashoda Hospitals , Gleneagles Global Hospitals , Excel Hospital , Natco Pharma Share Price , Elgene S , Natco Pharma , Atco Pharma Latest News , ஆந்திரா பிரதேஷ் , நாட்கோ பார்மா , ப்ரெக்கன்ரிட்ஜ் மருந்து இன்க் , யஷோட மருத்துவமனைகள் , க்ல்நேயேஜ்ல்ஸ் உலகளாவிய மருத்துவமனைகள் , எக்செல் மருத்துவமனை , நாட்கோ பார்மா பகிர் ப்ரைஸ் ,

Natco Pharma initiates Phase III clinical trial of Molnupiravir capsules


Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.
Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.
Phase-III clinical trial is initiated to evaluate the efficacy and safety of Molnupiravir Capsules in mild COVID-19 patients. NATCO s clinical trial is planned in 32 hospitals across India. A few established hospitals locally include Yashoda Hospitals, Gleneagles Global Hospitals, KIMS Hospital in Secunderabad and Vizag, and Excel Hospital, where the trial is being conducted.
Powered by Capital Market - Live News ....

Andhra Pradesh , Natco Pharma , Yashoda Hospitals , Molnupiravir Capsules , Gleneagles Global Hospitals , Excel Hospital , Capital Market , ஆந்திரா பிரதேஷ் , நாட்கோ பார்மா , யஷோட மருத்துவமனைகள் , க்ல்நேயேஜ்ல்ஸ் உலகளாவிய மருத்துவமனைகள் , எக்செல் மருத்துவமனை , மூலதனம் சந்தை ,